Company news
Icecure Medical Ltd. (NASDAQ:ICCM) news
Icecure Medical Ltd. news releases on 6ix. Latest, Oct 9, 2025: IceCure Medical to Attend the 2025 Maxim Growth Summit
Press releases — page 2
IceCure Medical to Attend the 2025 Maxim Growth Summit
October 9, 2025
IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care
October 3, 2025
IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above
October 3, 2025
IceCure's ProSense® at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented
September 30, 2025
IceCure's ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented
September 22, 2025
IceCure Granted Notice of Allowance for U.S. Patent for its Next-Generation XSense™ Cryoprobes
September 18, 2025
IceCure Receives Regulatory Approval in Israel for its Next-Generation XSense™ Cryoablation System for Breast Cancer and Other Indications
September 15, 2025
Two New Publications from the Independent THERMAC Trial Featuring IceCure's ProSense® in Breast Cancer Finds 95% of Patients Satisfied with Thermal Ablation; ProSense® Cryoablation Achieves Highest Complete Ablation Rate
September 8, 2025
IceCure's ProSense® Substantially Reduces Abdominal Wall Endometriosis Pain with High Procedural Efficacy
September 4, 2025
IceCure Reports Financial & Operational Results for the First Half of 2025
August 13, 2025
IceCure to Report First Half 2025 Financial and Operating Results on August 13, 2025
August 6, 2025
IceCure Announces Expiration and Results of Approximately Two Times Over-Subscribed Rights Offering for Aggregate Gross Proceeds of $10.0 Million
July 29, 2025
IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation
July 25, 2025
IceCure Reminds Shareholders of Upcoming Expiration of Rights Offering Subscription Period
July 24, 2025
IceCure Announces Commencement of Rights Offering
July 10, 2025
IceCure Reports Preliminary Financial Results for the Three and Six Months Ended June 30, 2025
July 3, 2025
IceCure Announces Record Date for Rights Offering for Up to $10 Million
June 25, 2025
IceCure Receives Notice of Patent Allowance in U.S. for a Novel Cryogen Flow Control to Optimize Patient Outcomes
June 9, 2025
IceCure Medical Reports First Quarter 2025 Financial Results
May 28, 2025
IceCure to Report First Quarter 2025 Financial & Operational Results on May 28, 2025
May 21, 2025
IceCure Receives High Level of Interest from Breast Surgeons at ASBrS 2025 Annual Meeting Following Recent Positive FDA Development on ProSense® Cryoablation
May 6, 2025
IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast Cancer
April 30, 2025
IceCure Exhibits ProSense® & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging Symposium
April 28, 2025
IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation
April 22, 2025
IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America
March 27, 2025
IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate
March 24, 2025
IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025
March 21, 2025
IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense® Cryoablation in Early-Stage Breast Cancer
March 20, 2025
IceCure's ProSense® Cryoablation Featured in Six Studies Presented at St. Gallen International Breast Cancer Conference
March 18, 2025
IceCure Receives Notice of Allowance in China for Novel Cryogenic Pump for Next-Generation Cryoablation Technology
March 17, 2025
Breast Cancer Patients who Underwent IceCure's ProSense® Cryoablation in Japan Reported Significantly Higher Satisfaction than Patients who Underwent Standard of Care Surgery
March 10, 2025
IceCure Submits Filing for Regulatory Approval of its Next-Generation XSense™ Cryoablation System in Israel
February 24, 2025
IceCure Files for Regulatory Approval of ProSense® Cryoablation System in China
January 26, 2025
IceCure Medical Regains Full Nasdaq Compliance with Nasdaq Minimum Closing Bid Price Rule
January 5, 2025
IceCure's ProSense® Cryoablation Safe and Effective in Destruction of Kidney Tumors with 88.7% Recurrence-Free Rate Based on Interim ICESECRET Study Results
December 4, 2024
IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense® Cryoablation
November 25, 2024
IceCure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance from Japan's Patent Office
November 24, 2024
IceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health
November 18, 2024
IceCure Receives Notice of Allowance from U.S. Patent and Trademark Office for its Next-Generation Cryoablation System
October 20, 2024
IceCure Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense® in Early-Stage Low Risk Breast Cancer Scheduled for November 7, 2024
September 11, 2024
USPTO Grants Notice of Allowance for Additional Patent on IceCure's Novel Cryogenic Pump Technology: Reinforces IceCure's Global IP Leadership in Cryoablation Technologies
August 27, 2024
IceCure Medical Reports 20% Growth in ProSense® System and Probe Sales for the First Half of 2024; Reflects Continued Adoption in the U.S. and Other Global Markets
August 19, 2024
IceCure's ProSense® Destroyed 100% of Breast Cancer Tumors in Independent Study of Patients Who Chose Cryoablation Instead of Surgery
August 13, 2024
IceCure Announces Positive Data from the Largest Multi-Institutional Study of its Kind: "Cryoablation of Primary Breast Cancer in Patients Ineligible for Clinical Trials"
August 6, 2024
U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense™ Cryoablation System with CryoProbes
June 30, 2024
Positive Data from IceCure's Kidney Cancer Clinical Study Presented at Interventional Radiology Conference: Minimally Invasive Approach Results in Shorter Hospitalization and Minor Impact on Renal Function
June 11, 2024
IceCure Medical Maintains Positive Momentum and Reports Sales Growth for Cryoablation System in First Quarter of 2024
May 27, 2024
IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast Cancer
April 14, 2024
IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense® and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing Clearance
April 2, 2024
IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with Cryoprobes
April 1, 2024